Skip to content
HowShorted

Iovance Biotherapeutics, Inc. short interest in 2022

In 2022, Iovance Biotherapeutics, Inc.'s disclosed short interest ran from 7.66% of shares outstanding on 14 Jan 2022 to 13.75% on 30 Dec 2022, a change of +6.09 percentage points. The year's high was 13.75% on 30 Dec 2022 and its low 7.16% on 31 Jan 2022, averaging 10.90% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.79 days on 15 Sep 2022. Full history: Iovance Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Iovance Biotherapeutics, Inc. in 2022

2022 in figures

Start of year
7.66% (14 Jan 2022)
End of year
13.75% (30 Dec 2022)
Change
+6.09 pp
High
13.75% (30 Dec 2022)
Low
7.16% (31 Jan 2022)
Average
10.90%
Highest days to cover
9.79 (15 Sep 2022)
SEC filings marked
8

Every report in 2022

Iovance Biotherapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20227.66%3.93
31 Jan 20227.16%5.05
15 Feb 20227.99%7.94
28 Feb 20228.74%8.0110-K filed, results (8-K)
15 Mar 20228.72%8.21
31 Mar 20228.85%5.66
14 Apr 20229.72%5.25
29 Apr 202210.06%9.19
13 May 202210.94%7.5710-Q filed, results (8-K)
31 May 202211.05%2.85
15 Jun 202210.53%1.92
30 Jun 202213.71%2.95
15 Jul 202212.69%6.05
29 Jul 202212.31%7.52
15 Aug 202213.15%8.6010-Q filed, results (8-K)
31 Aug 202212.45%8.55
15 Sep 202212.38%9.79
30 Sep 202211.83%8.46
14 Oct 202211.51%8.03
31 Oct 202210.94%9.34
15 Nov 202211.56%5.8110-Q filed, results (8-K)
30 Nov 202211.86%4.12
15 Dec 202212.09%2.47
30 Dec 202213.75%5.34

See also: Iovance Biotherapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.